Human tuberculosis remains a huge global public health problem with an estimated 1/3rd of the population being infected. Defensins are antibacterial cationic peptides produced by a number of cell types, most notably neutrophil granulocytes and epithelial cells. All three defensin types (α‐, β‐, and θ‐defensins) have antibacterial activities, mainly through bacterial membrane permeabilization. Defensins are effective against Gram‐negative and Gram‐positive bacteria including mycobacteria and are active both intra‐ and extracellularly. Mycobacterial resistance has never been demonstrated although the mprF gene encoding resistance in Staphylococcus aureus is present in the Mycobacterium tuberculosis genome. In addition to their antibacterial effect, defensins are chemoattractants for macrophages and neutrophils. There are many cases for their use for therapy or prophylaxis in tuberculosis as well. In conclusion, we propose that there is considerable scope and potential for exploring their use as therapeutic/prophylactic agents and more comprehensive survey of defensins from different species and their bioactivity is timely.
Defensins: The Case for Their Use against Mycobacterial Infections
Haodi Dong,Yue Lv,Deming Zhao,P. Barrow,Xiangmei Zhou
Published 2016 in Journal of Immunological Research
ABSTRACT
PUBLICATION RECORD
- Publication year
2016
- Venue
Journal of Immunological Research
- Publication date
2016-09-20
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
CITED BY
Showing 1-45 of 45 citing papers · Page 1 of 1